Abstract: Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

Abstract: Provided is a recombinant vector including a porcine Fc fragment. By fusing the porcine Fc fragment with various target proteins by using the recombinant vector of the present invention, not only target proteins may be expressed using various hosts including plants, but the productivity and stability of target proteins may also be increased.

Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z.

Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.

Abstract: Cas9-inhibiting polypeptide compositions and methods are provided.

Abstract: Disclosed are catalytically active water-insoluble protein aggregates comprising fusion proteins which comprise a coiled-coil domain and a catalytic domain, methods of manufacturing such protein aggregates, and their use.

Abstract: Provided is a bacterial strain which produces a family of mosquitocidal toxins, Xenorhabdus MT, on deposit with the American Type Culture Collection, PTA-6826, insecticidal compositions comprising the mosquitocidal toxin(s) produced by Xenorhabdus MT, a mosquitocidal toxin preparation prepared from spent culture medium, whole culture or cells or a mixture thereof, of Xenorhabdus MT and method of insect control, especially mosquito control. Also provided are microbial compounds (same as mosquitocidal toxins) compositions comprising them and use in formulating therapeutic and other antimicrobial compositions, and methods of use for inhibiting microbial growth and for treating infection.

Abstract: The present invention discloses a strain of bacteria producing DHA and/or EPA, six gene fragments in the bacterial genome, and uses thereof. The strain is Schizoochytrium limacinum HS01, which has the accession number of CGMCC No. 13746 at China General Microbiological Culture Collection Center. The six gene fragments are composed of gene fragment 1 to gene fragment 6, and the nucleotide sequences are sequentially as shown in SEQ ID NO: 3 to SEQ ID NO: 8 in the Sequence Listing. The experiments prove that fermentation broth containing DHA and EPA can be obtained by fermenting Schizoochytrium limacinum HS01; the recombinant strain is obtained by introducing gene fragment 1 to gene fragment 6 into Schizoochytrium limacinum MYA-1381; the ability the recombinant strain for producing DHA and EPA is greatly improved.

Abstract: Disclosed herein are engineered light-sensitive proteins, for example channelrhodopsins and variants thereof. Also disclosed are compositions for expressing the light-sensitive proteins in cells, tissues, organs and subjects, and methods for using the light-sensitive proteins to, for example, enable minimally-invasive neuronal circuit interrogation in living organism, and treat neuronal and ocular disorders.

Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.

Abstract: The present invention provides for a recombinant or isolated polypeptide comprising the amino acid sequence of an enhancer polypeptide associated with a diarrhea disorder; a transgenic non-human mammal, wherein the mammal is deleted or knocked out for one or more of an intestine-critical region (ICR); a pharmaceutical composition comprising the polypeptide of the present invention and a pharmaceutical acceptable carrier; and, a method of treating or preventing a subject suffering or at risk or suspected of suffering from a diarrhea disease or disorder, the method comprising administrating a pharmaceutical composition of the present invention to a subject in need of such treatment.

Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.

Abstract: The present invention provides a recombinant fusion protein. The fusion protein is formed by the fusion of D2 domain of Slit2 protein and HSA protein, and the position 386 amino acid of the Slit2 protein molecule is serine.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: In certain aspects, the present disclosure relates to methods of treating, preventing, and reducing the severity or progression of heart failure or one or more complications of heart failure. For example, the disclosure provides various BMP antagonists, such as ActRIIA polypeptides, ActRIIB polypeptides, BMPRII polypeptides, ALKI polypeptides, endoglin polypeptides, BMP 10 propeptide proteins and Fc fusion proteins thereof as well as anti-BMP9 antibodies, for treating, preventing and reducing the severity or progression of heart failure or one or more complications of heart failure.

Abstract: Compositions and methods involving IL40, a novel cytokine produced by activated B cells, are provided. The compositions include: a) anti-IL40 antibodies, IL40 peptides and IL40 proteins; b) nucleic acids encoding IL40 gene and cDNA sequences; and c) pharmaceutical compositions thereof. The methods include treatments, diagnostics and isolation technologies.

Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.

Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.

Abstract: Disclosed herein are methods of using relaxin polypeptides and analogs, or nucleic acid molecules encoding such polypeptides to treat or inhibit atrial fibrillation.

Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIP5-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.

Abstract: The disclosure shows that inflammation in metabolic syndrome is augmented by a hitherto overlooked lock-and-key activation of the elastin receptor, a protein involved in vascular (blood vessel) inflammation and elastin repair, with the C-peptide, a small protein that is produced in a 1:1 ratio alongside with widely known insulin. The elastin receptor is the lock that is activated by a key motif of amino acids (PG-domain) found in C-peptide and in breakdown products (PG-domain-fragments) thereof. Until now, no one has ever discovered this lock-and-key interaction between the two, now providing novel inroads in diagnosis, prevention and development of novel compounds for treatment of metabolic syndrome, exploiting the finding that not only the normal keys of the elastin receptor (elastin peptides), but also the C-peptide, a peptide we produce together with insulin every time glucose rises in our blood after a meal, interacts in a lock-and-key mode with the elastin receptor.

Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with altered expression and/or function of one or more genes, e.g., associated with Tet2, and methods of use therefore. The invention further provides inhibitors of the one or more genes and methods of use therefore in connection with CAR T cells.

Abstract: A multifunctional fusion protein and applications thereof. The multifunctional fusion protein comprising a. functional domains that recognize CD47 positive tumor cells: the extracellular portion of SIRP?, b. functional domains that recognize PD-L1-positive tumor cells: the extracellular portion of PD-1, and c. functional domains that bind to immune cells: high-affinity human IgG1Fc portion. The fusion protein of the invention can meet the needs of the patients for tumor immunotherapy. The recombinant fusion protein can recognize CD47 and PD-L1-positive tumor cells, and bind with immune effector cells containing Fc receptors.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

Abstract: It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain.

Abstract: This invention provides isolated human antibodies and recombinant proteins comprising defined heavy chains and light chains, wherein the antibodies and recombinant proteins neutralize Andes Virus with defined IC50 values. This invention also provides related pharmaceutical compositions, treatment methods and kits.

Abstract: The present invention relates to a method for reducing the occurrence and/or severity of viral infections. The method embodies procedures for expanding HIV from the blood of HIV antibody negative donors and deriving a non-infectious virus particle product that is antigenic. The procedures for deriving the antigenic, non-infectious virus particle product are optimally designed to maintain the integrity of the envelope proteins while maximizing the depletion of capsid proteins and RNA. The resulting virus particle product, when introduced into humans or non-human animals, enables the production of antibodies that target the natural envelope macromolecular structure that is required for infectivity. The present invention can be applied to producing virus stocks from the blood of HIV-seronegative donors, for deriving non-infectious virus particles that retain intact envelope proteins, for producing anti-viral antibodies, and for administering anti-virus antibodies to patients.

Abstract: Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.

Abstract: The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.

Abstract: The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, wherein the method may be used to evaluate haemophilic disease.

Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomelic tau, fibrillar tau or non-disease associated forms of tau.

Abstract: Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest.

Abstract: The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

Abstract: Stable adalimumab formulations are disclosed.

Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.

Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: Provided is an antibody or a fragment thereof, which can be specifically bound to an S3-4 ring of a voltage sensor paddle of a domain III of voltage-gated sodium channel Nav1.9 ? sub-unit, and is able to inactivate a voltage sensor valve to keep sodium ions from entering nerve cells normally. Also provided is an epitope polypeptide specifically bound to the antibody or the fragment thereof, a pharmaceutical composition comprising the antibody or the fragment thereof, and a use of the antibody or the fragment thereof in preparing a drug for treating and diseases related to pains.

Abstract: Disclosed is an antibody targeting at least one ligand from an immune checkpoint, having a region Fc that is mutated in relation to that of a parent antibody and has an improved affinity for the receptor FcgRIIIa (CD16a) and/or a higher ADCC activity than the parent antibody.

Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: The present invention relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD- 11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

Abstract: The invention relates to T cell-targeted T cells, and methods employed in their production.

Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.